These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 31639786)

  • 1. Effects of Glutathione Transferase-Targeting Nitrobenzoxadiazole Compounds in Relation to PD-L1 Status in Human Melanoma Cells.
    Sciarretta F; Fulci C; Palumbo C; Rotili D; Tentori L; Graziani G; Caccuri AM
    Chemotherapy; 2019; 64(3):138-145. PubMed ID: 31639786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis.
    De Luca A; Carpanese D; Rapanotti MC; Viguria TM; Forgione MA; Rotili D; Fulci C; Iorio E; Quintieri L; Chimenti S; Bianchi L; Rosato A; Caccuri AM
    Oncotarget; 2017 Feb; 8(9):15520-15538. PubMed ID: 28107182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Jun N-terminal kinase activation by nitrobenzoxadiazoles leads to late-stage autophagy inhibition.
    Palumbo C; De Luca A; Rosato N; Forgione M; Rotili D; Caccuri AM
    J Transl Med; 2016 Feb; 14():37. PubMed ID: 26847645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells.
    Górniak P; Wasylecka-Juszczyńska M; Ługowska I; Rutkowski P; Polak A; Szydłowski M; Juszczyński P
    Mol Oncol; 2020 Aug; 14(8):1817-1832. PubMed ID: 32330348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts.
    De Luca A; Rotili D; Carpanese D; Lenoci A; Calderan L; Scimeca M; Mai A; Bonanno E; Rosato A; Geroni C; Quintieri L; Caccuri AM
    Oncotarget; 2015 Feb; 6(6):4126-43. PubMed ID: 25595904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
    Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
    J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
    Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
    Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
    Atefi M; Avramis E; Lassen A; Wong DJ; Robert L; Foulad D; Cerniglia M; Titz B; Chodon T; Graeber TG; Comin-Anduix B; Ribas A
    Clin Cancer Res; 2014 Jul; 20(13):3446-57. PubMed ID: 24812408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer.
    Filomeni G; Turella P; Dupuis ML; Forini O; Ciriolo MR; Cianfriglia M; Pezzola S; Federici G; Caccuri AM
    Mol Cancer Ther; 2008 Feb; 7(2):371-9. PubMed ID: 18281520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.
    Wongchenko MJ; Ribas A; Dréno B; Ascierto PA; McArthur GA; Gallo JD; Rooney IA; Hsu J; Koeppen H; Yan Y; Larkin J
    Pigment Cell Melanoma Res; 2018 Jul; 31(4):516-522. PubMed ID: 29156488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
    Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
    Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma.
    Pellizzari Tregno F; Sau A; Pezzola S; Geroni C; Lapenta C; Spada M; Filomeni G; Bonanno E; Federici G; Caccuri AM
    Eur J Cancer; 2009 Sep; 45(14):2606-17. PubMed ID: 19665369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy inhibition enhances PD-L1 expression in gastric cancer.
    Wang X; Wu WKK; Gao J; Li Z; Dong B; Lin X; Li Y; Li Y; Gong J; Qi C; Peng Z; Yu J; Shen L
    J Exp Clin Cancer Res; 2019 Mar; 38(1):140. PubMed ID: 30925913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
    Zhang D; Reyes RM; Osta E; Kari S; Gupta HB; Padron AS; Kornepati AVR; Kancharla A; Sun X; Deng Y; Wu B; Vadlamudi R; Li R; Svatek RS; Curiel TJ
    Cancer Med; 2021 Mar; 10(6):2137-2152. PubMed ID: 33626233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
    Tentori L; Dorio AS; Mazzon E; Muzi A; Sau A; Cuzzocrea S; Vernole P; Federici G; Caccuri AM; Graziani G
    Eur J Cancer; 2011 May; 47(8):1219-30. PubMed ID: 21269821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
    Clark CA; Gupta HB; Sareddy G; Pandeswara S; Lao S; Yuan B; Drerup JM; Padron A; Conejo-Garcia J; Murthy K; Liu Y; Turk MJ; Thedieck K; Hurez V; Li R; Vadlamudi R; Curiel TJ
    Cancer Res; 2016 Dec; 76(23):6964-6974. PubMed ID: 27671674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.
    Massi D; Brusa D; Merelli B; Ciano M; Audrito V; Serra S; Buonincontri R; Baroni G; Nassini R; Minocci D; Cattaneo L; Tamborini E; Carobbio A; Rulli E; Deaglio S; Mandalà M
    Ann Oncol; 2014 Dec; 25(12):2433-2442. PubMed ID: 25223485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
    Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
    J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.
    Kim MH; Kim CG; Kim SK; Shin SJ; Choe EA; Park SH; Shin EC; Kim J
    Cancer Immunol Res; 2018 Mar; 6(3):255-266. PubMed ID: 29382670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.